(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 August 2021 (12.08.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/156267 A1

(51) International Patent Classification:
A61K 39/12 (2006.01) *A61P 11/00* (2006.01)
A61K 39/215 (2006.01) *A61P 31/14* (2006.01)

(21) International Application Number:
PCT/EP2021/052455

(22) International Filing Date:
03 February 2021 (03.02.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

PCT/EP2020/052775		
	04 February 2020 (04.02.2020)	EP
PCT/EP2020/059687		
	03 April 2020 (03.04.2020)	EP
PCT/EP2020/065091		
	29 May 2020 (29.05.2020)	EP
PCT/EP2020/079831		
	22 October 2020 (22.10.2020)	EP
PCT/EP2020/079973		
	23 October 2020 (23.10.2020)	EP
PCT/EP2020/080713		
	02 November 2020 (02.11.2020)	EP
63/112,106	10 November 2020 (10.11.2020)	US
63/113,159	12 November 2020 (12.11.2020)	US
63/119,390	30 November 2020 (30.11.2020)	US
63/129,395	22 December 2020 (22.12.2020)	US

(71) Applicant: **CUREVAC AG** [DE/DE]; Friedrich-Miescher-Str. 15, 72076 Tübingen (DE).

(72) Inventors: **RAUCH, Susanne**; c/o IP Department, CureVac AG, Friedrich-Miescher-Str. 15, 72076 Tübingen (DE). **GROSSE, Hans Wolfgang**; c/o IP Department, CureVac AG, Friedrich-Miescher-Str. 15, 72076 Tübingen (DE). **PETSCH, Benjamin**; c/o IP Department, CureVac AG, Friedrich-Miescher-Str. 15, 72076 Tübingen (DE).

(74) Agent: **GRAF VON STOSCH PATENTANWALTSGESELLSCHAFT MBH** et al.; Prinzregentenstr. 22, 80538 Munich (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: CORONAVIRUS VACCINE

(57) Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

WO 2021/156267 A1